Cambridge Healthtech Institute’s 15th Annual

Target Identification & Validation 
( 标靶识别及验证)

Part 1: Focus on Functional Genomics & Computational Screening


Part 2: Focus on Chemical Biology & Phenotypic Screening


Finding novel, druggable targets for therapeutic intervention remains a top priority for the pharma/biotech industry, especially when it comes to building a robust drug discovery pipeline. It also remains a formidable challenge and companies continue to invest a lot of time and resources in identifying and validating good drug targets to pursue. What are the challenges in target discovery? What tools and strategies are being used and how well are they working? What’s being done to ensure that validated targets lead to better and safer therapies? Cambridge Healthtech Institute’s conference on Target Identification & Validation will bring together leading experts to discuss some of these critical questions. The conference will help attendees meet and interact with experts and peers from around the world to share ideas and hear about new strategies and technologies helping target discovery.


Who should attend: SCIENTISTS and EXECUTIVES from Pharma, Biotech, Academia, Government, Contract Research Labs and Technology Providers involved in target ID & validation, discovery biology, biochemistry, molecular & cell biology, high-throughput screening, phenotypic screening, functional genomics, chemical biology, computational biology, bioinformatics, and other areas related to early drug discovery & development.


Part 1:

This part of the Target Identification & Validation conference will highlight some of the existing and emerging functional genomics, artificial intelligence and machine learning tools that are being used for generating novel drug targets. The use of such tools and screens for validating exisiting targets or associating them with new disease indications will also be discussed.


Coverage will include, but is not limited to:

  • Use of CRISPR, RNAi, and chemical genomic screens for finding novel targets
  • Emerging functional genomic assays and platforms for target identification and phenotypic screening
  • Use of single-cell analysis and next-gen sequencing for target validation
  • Exploring artificial intelligence and machine learning tools for target identification and characterization
  • Using databases, data visualization tools for associating targets and diseases
  • Complementary use of technologies for target deconvolution and validation
  • Seeking out difficult, high-value targets using genomic data
  • Learning how to prioritize druggable targets for follow-up studies


Part 2:

This part of the Target Identification & Validation conference will describe how phenotypic screening and chemical biology can be used to find new drug targets, validate existing targets for new indications, and better understand how inhibiting or activating these targets could impact other cellular pathways.


Coverage will include, but is not limited to:

  • Exploring various models, assays and platforms for phenotypic screening
  • Emerging chemical biology, label-free, microfluidic, and other screening tools
  • Chemoproteomic profiling for target identification and mechanism-of-action studies
  • Effectively using chemical probes for target identification, deconvolution and characterization
  • Virtual screening and computational approaches for finding novel targets
  • Case studies on how to deconvolute and prioritize druggable targets from screening hits

* 活动内容有可能不事先告知作更动及调整。

Choose your language